Practical guidelines for the diagnosis and treatment of transthyretin amyloid cardiomyopathy (ATTR-CM or transthyretin cardiac amyloidosis)

被引:4
|
作者
Tereshchenko, Sergey N. [1 ,2 ]
Zhirov, Igor, V [1 ,2 ]
Moiseeva, Olga M. [3 ,4 ]
Adasheva, Tatiana, V [5 ]
Ansheles, Alexey A. [1 ]
Barbarash, Olga L. [6 ,7 ]
Galyavich, Albert S. [8 ]
Gudkova, Alexandra Ja [3 ,4 ]
Zateyshchikov, Dmitry A. [9 ,10 ]
Kostareva, Anna A. [3 ]
Nasonova, Svetlana N. [1 ]
Nedogoda, Sergey, V [11 ]
Pecherina, Tamara B. [6 ]
Ryzhkova, Daria, V [3 ]
Sergienko, Vladimir B. [1 ]
机构
[1] Chazov Natl Med Res Ctr Cardiol, Moscow, Russia
[2] Russian Med Acad Continuous Profess Educ, Moscow, Russia
[3] Almazov Natl Med Res Ctr, St Petersburg, Russia
[4] Pavlov First St Petersburg State Med Univ, St Petersburg, Russia
[5] Yevdokimov Moscow State Univ Med & Dent, Moscow, Russia
[6] Res Inst Complex Problems Cardiovasc Dis, Kemerovo, Russia
[7] Kemerovo State Med Univ, Kemerovo, Russia
[8] Kazan State Med Univ, Kazan, Russia
[9] City Clin Hosp 51, Moscow, Russia
[10] Cent State Med Acad President Russian Federat, Moscow, Russia
[11] Volgograd State Med Univ, Volgograd, Russia
关键词
transthyretin amyloid cardiomyopathy; clinical guidelines; diagnosis; heart failure with preserved ejection fraction; scintigraphy; RECOMMENDATIONS; MANAGEMENT; TAFAMIDIS; PATHOPHYSIOLOGY; EXPERIENCE; HEART;
D O I
10.26442/00403660.2022.04.201465
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This paper summarizes the data from updated international protocols and guidelines for diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM). The invasive and non-invasive diagnosis techniques and their combinations are briefly reviewed; the evidentiary foundations for each diagnostic option and tool are analyzed. The paper describes a customized algorithm for sequential diagnosis and differential diagnosis of patients with suspected ATTR-CM with allowance for the combination of clinical signs and diagnostic findings. Along with the awareness of primary care providers about the red flags of the disease and visualization criteria, as well as providing information to the patients about the possibility of performing therapy of ATTR amyloidosis and the risks of delayed diagnosis, the proposed algorithm enables timely patient routing and prescribing specific treatment.
引用
收藏
页码:584 / 595
页数:12
相关论文
共 50 条
  • [21] Tafamidis for the treatment of transthyretin cardiac amyloidosis (ATTR-CM) - Real-world data from a tertiary center
    Carvalho, R.
    Rocha, B.
    Maltes, S.
    Cunha, G.
    Marques, A.
    Laranjeira, T.
    Brizido, C.
    Adragao, P.
    Mendes, M.
    Aguiar, C.
    EUROPEAN HEART JOURNAL, 2024, 45
  • [22] Indication and electrical performance of conventional, resynchronisation and conduction system pacing in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
    Dobner, Stephan
    Tawo, Serlha
    Wieser, Fabian
    Graeni, Christoph
    Haeberlin, Andreas
    CIRCULATION, 2024, 150
  • [23] RECOGNIZING, DIAGNOSING, AND TREATING TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM): TARGETING CONTINUING MEDICAL EDUCATION (CME) TO THOSE WHO AREN'T TREATING ATTR-CM
    Murley, Yvette M.
    Bender, Steve
    Heeg, Marlene O.
    Simmons, Jonathan S.
    LaTemple, Denise C.
    Lin, Grace
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 3342 - 3342
  • [24] DOUBLE TROUBLE: A CASE OF SUPERIMPOSED TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) IN A PATIENT WITH ESTABLISHED HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY (HOCM)
    Steingauer, Veronika
    Akiki, Elias
    Abbasi, Muhannad
    El-Am, Edward
    Ahmad, Ali
    Bratt, Alexander
    Kurmann, Reto
    Klarich, Kyle W.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 4317 - 4317
  • [25] Detecting transthyretin amyloid cardiomyopathy (ATTR-CM) using machine learning: an evaluation of the performance of an algorithm in a UK setting
    Tsang, Carmen
    Huda, Ahsan
    Norman, Max
    Dickerson, Carissa
    Leo, Vincenzo
    Brownrigg, Jack
    Mamas, Mamas
    Elliott, Perry
    BMJ OPEN, 2023, 13 (10):
  • [26] Race, Sex, and Ejection Fraction-Based Differences in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Risk Prediction
    El Helou, Michel Chedid
    Gupta, Mohak
    Hussain, Muzna
    Hanna, Mazen
    Blumer, Vanessa
    William, Preethi
    Desai, Milind Y.
    Abadie, Bryan Q.
    Ives, Lauren
    Tang, W. H. Wilson
    Jaber, Wael A.
    Collier, Patrick
    Martyn, Trejeeve
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (20)
  • [27] Delays in diagnostic tests used to identify transthyretin amyloid cardiomyopathy (ATTR-CM) in the EU4+UK
    Deemer, J.
    Melinis, N.
    Brown, S.
    Chung, W. Y.
    EUROPEAN HEART JOURNAL, 2021, 42 : 1737 - 1737
  • [28] REAL-WORLD MEDICATION ADHERENCE TO TAFAMIDIS TREATMENT IN PATIENTS WITH TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) IN THE US MEDICARE POPULATION
    Kemner, Jason
    Cantu, Cera
    Alvir, Jose
    Chen, Yong
    Sounthonevat, Cindi
    Chung, Haechung
    Prasad, Sapna
    Bhambri, Rahul
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (08) : 401 - 401
  • [29] Cardiac microcalcifications in transthyretin (ATTR) amyloidosis
    Thelander, Ulrika
    Westermark, Gunilla T.
    Antoni, Gunnar
    Estrada, Sergio
    Zancanaro, Alice
    Ihse, Elisabet
    Westermark, Per
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2022, 352 : 84 - 91
  • [30] Validation of the ATTR-CM score for transthyretin amyloid cardiomiopathy in a mediterranean cohort of patients at risk
    Cediel, G.
    Santesmases, J.
    Domingo, M.
    Moragas, G.
    Sola, M.
    Garcia-Calvo, X.
    Guix, G.
    Pacho, C.
    Santiago-Vacas, E.
    Borrellas, A.
    Codina, P.
    Figuerola, N.
    Ruiz-Cueto, M.
    Lupon, J.
    Bayes-Genis, A.
    EUROPEAN HEART JOURNAL, 2023, 44